期刊文献+

GM1联合生长因子诱导骨髓间充质干细胞分化为神经元样细胞的研究 被引量:2

Study on the differentiation of bone marrow mesenchymal stem cells into neuron-like cells by GM1 and growth factors
下载PDF
导出
摘要 目的:探讨单唾液酸四己糖神经节苷脂(monosialoteterahexosyl ganglioside,GM1)联合生长因子(bFGF+EGF)能否更为高效地促进骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)分化为神经元样细胞,从而为细胞替代治疗缺血性脑卒中提供实验依据。方法:采用密度梯度离心法获取骨髓单个核细胞,行原代、传代培养,取第3代BMSCs,用流式细胞术鉴定其表面标志物;同时鉴定其多分化潜能。将第3代BMSCs分四组向神经元样细胞诱导分化,A组:单用(bFGF+EGF);B组:单用GM1;C组:GM1联合(bFGF+EGF);D组:对照组。分别在正式诱导前后行免疫细胞化学法检测各组细胞Nestin、β-TubulinⅢ、GFAP的阳性表达率并行数据统计分析。结果:流式细胞术鉴定BMSCs表面标志物呈CD29(+)、CD105(+)、CD34(-)、CD45(-);同时其具分化为成骨细胞和成脂细胞潜能。BMSCs诱导为神经元样细胞之前,四组细胞Nestin、β-Tubulin、GFAP表达均呈阴性;诱导2~4 d时,A、B、C三组Nestin阳性细胞表达率均呈上升趋势,且C组高于A、B、D组;诱导6~8 d时,A、B、C三组Nestin阳性细胞表达率均有所降低,而β-TubulinⅢ、GFAP阳性细胞表达率则呈较明显上升趋势,且C组较A、B组升高明显。综合实验数据,C组Nestin、β-TubulinⅢ、GFAP阳性细胞表达率均高于A、B、D组。结论:GM1联合生长因子(bFGF+EGF)相比单独的生长因子(bFGF+EGF)或GM1,可更为高效地促进BMSCs诱导分化为神经元样细胞。 Objective:To approach a way to more efficiently induce BMSCs(bone marrow mesenchymal stem cells) into neuron-like cells by GM1(monosialoteterahexosyl ganglioside) combined with growth factors(bFGF + EGF) differentiatly and supply experimental evidence for cell replacement therapy to ischemia stroke.Methods:Bone marrow mononuclear cells were obtained by density gradient centrifugation,then primary culture and subculture was proceed,and surface markers of the third passage BMSCs were identified by flow cytometry.Meanwhile,pluripotency of BMSCs were identified.Subsequently,BMSCs were divided into four groups in order to induce into neuron-like cells with different inducers.Group A:(bFGF + EGF) alone,group B:GM1 alone,group C:GM1 and growth factors(bFGF + EGF) and group D:control group.Respectively,the positive rate of Nestin,β-Tubulin Ⅲ and GFAP were detected by using immunocytochemistry before and after induction and the data was statistically analyzed.Results:The positive rate of surface markers of BMSCs were CD29(+),CD105(+),CD34(-),CD45(-) by flow cytometry.Meanwhile,the BMSCs induced into osteoblasts and adipocytes were detected.Before BMSCs induced into neuron-like cells,the rate of Nestin,β-Tubulin Ⅲand GFAP were negative in four group.On the 2nd to 4th day for induction,the Nestin positive rate of group A,B and C showed an upward trend,and that group C was much higher than group A,B and D.On the 6th to 8 th day for induction,the Nestin positive rate of group A,B and C decreased,however,the β-Tubulin Ⅲ and GFAP positive rate was detected significantly upward trend,and that group C was higher than group A and B.Comprehensive experimental data,the Nestin,β-Tubulin Ⅲ and GFAP positive rate of group C were higher than group A,B and D.Conclusion:GM1 combined with growth factors(bFGF + EGF) group can more effectively induce BMSCs into neuron-like cells in comparison with growth factors(bFGF + EGF) group or GM1 group.
出处 《神经解剖学杂志》 CAS CSCD 北大核心 2015年第6期757-764,共8页 Chinese Journal of Neuroanatomy
基金 浙江省医学会临床科研基金(2013XYC-A73)
关键词 骨髓间充质干细胞 GM1 生长因子 诱导 神经元样细胞 BMSCs GM1 growth factors induce neuron-like cells
  • 相关文献

参考文献1

二级参考文献99

  • 1Wahlgren N, Ahrced N, Davalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet, 2007, 369: 275-282.
  • 2Lyden PD, ed. Thrombolytic Therapy for Acute Stroke. 2nd ed. Totowa, NJ: Hmreana Press, 2005.
  • 3Wardlaw JM, Smdercock PA, Berg: E. Throrrbolytic therapy with recoinbinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cunaflative meta-analysis. Stroke, 2003, 34: 1437-1442.
  • 4Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2003, (4): CD000213.
  • 5Shanna M, Clark H, Armour T, et al. Acute stroke: evaluation and treatment. Evid Rep Technol Assess (Sunmm), 2005, (127): 1-7.
  • 6Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Throrrbolysis for acute ischemic stroke: results of the Canadian Altephse for Stroke Effectiveness Study. CMAJ, 20(0, 172: 1307-1312.
  • 7Chung H, Refoios Canto R, Canto RR, et al. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart, 2007, 93: 1616-1617.
  • 8Saver JL, Smith EE, Fonarow GC, et al; GWTG-stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in > 30,000 patients ariving within 60 minutes of stroke onset. Stroke, 2010, 41: 1431-1439.
  • 9Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergmcy physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke, 2010, 41: 2026-2032.
  • 10Kwiatkowski TG, Libman RB, Fmnkel M, et al. Effects of tissue plasrrfinogen activator for acute ischemic stroke at one year. National Institute of Neurological Disordeis and Stroke Recombinxaat Tissue Plasmiogen Activator Stroke Study Group. N Engl J Med, 1999, 340: 1781-1787.

共引文献992

同被引文献5

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部